+

WO2006056696A3 - 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation - Google Patents

2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation Download PDF

Info

Publication number
WO2006056696A3
WO2006056696A3 PCT/FR2005/002932 FR2005002932W WO2006056696A3 WO 2006056696 A3 WO2006056696 A3 WO 2006056696A3 FR 2005002932 W FR2005002932 W FR 2005002932W WO 2006056696 A3 WO2006056696 A3 WO 2006056696A3
Authority
WO
WIPO (PCT)
Prior art keywords
alcoxy
alkylamides
trihydroxy
preparation
compositions containing
Prior art date
Application number
PCT/FR2005/002932
Other languages
English (en)
Other versions
WO2006056696A2 (fr
Inventor
Jidong Zhang
Neerja Bhatnagar
Jean-Marie Ruxer
Original Assignee
Aventis Pharma Sa
Jidong Zhang
Neerja Bhatnagar
Jean-Marie Ruxer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002595305A priority Critical patent/CA2595305A1/fr
Priority to MX2007006241A priority patent/MX2007006241A/es
Priority to BRPI0516666-7A priority patent/BRPI0516666A/pt
Priority to AU2005308710A priority patent/AU2005308710A1/en
Priority to EP05822934A priority patent/EP1819679A2/fr
Priority to EA200701172A priority patent/EA011392B1/ru
Priority to JP2007542046A priority patent/JP2008521780A/ja
Application filed by Aventis Pharma Sa, Jidong Zhang, Neerja Bhatnagar, Jean-Marie Ruxer filed Critical Aventis Pharma Sa
Publication of WO2006056696A2 publication Critical patent/WO2006056696A2/fr
Publication of WO2006056696A3 publication Critical patent/WO2006056696A3/fr
Priority to TNP2007000137A priority patent/TNSN07137A1/fr
Priority to IL183044A priority patent/IL183044A0/en
Priority to US11/753,160 priority patent/US7550453B2/en
Priority to NO20073026A priority patent/NO20073026L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

2-Alcoxy-3,4,5-trihydroxy-alkylamides, leur préparation, compositions les contenant et utilisation. La présente invention concerne notamment des 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur préparation, des compositions les contenant, et leur utilisation comme médicament, en particulier en tant qu'agents anticancéreux.
PCT/FR2005/002932 2004-11-29 2005-11-25 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation WO2006056696A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2007006241A MX2007006241A (es) 2004-11-29 2005-11-25 2-alcoxi-3,4,5-trihidroxi-alquilamidas, su preparacion, composiciones que las contienen y su utilizacion.
BRPI0516666-7A BRPI0516666A (pt) 2004-11-29 2005-11-25 2-alcóxi-3,4,5-trihidróxi-alquilamidas, o respectivo preparo, composições que as contém e a respectiva utilização
AU2005308710A AU2005308710A1 (en) 2004-11-29 2005-11-25 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
EP05822934A EP1819679A2 (fr) 2004-11-29 2005-11-25 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
EA200701172A EA011392B1 (ru) 2004-11-29 2005-11-25 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
CA002595305A CA2595305A1 (fr) 2004-11-29 2005-11-25 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
JP2007542046A JP2008521780A (ja) 2004-11-29 2005-11-25 ２−アルコキシ−３，４，５−トリヒドロキシアルキルアミド系化合物、この調製、これを含有する組成物、および、この使用
TNP2007000137A TNSN07137A1 (en) 2004-11-29 2007-04-13 2-alcoxy-3,4,5-trihydroxy-alkylamides,leur preparation, compositions les contenant et utilisation
IL183044A IL183044A0 (en) 2004-11-29 2007-05-07 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
US11/753,160 US7550453B2 (en) 2004-11-29 2007-05-24 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
NO20073026A NO20073026L (no) 2004-11-29 2007-06-13 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0412645 2004-11-29
FR0412645A FR2878528B1 (fr) 2004-11-29 2004-11-29 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/753,160 Continuation US7550453B2 (en) 2004-11-29 2007-05-24 2-alkoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof

Publications (2)

Publication Number Publication Date
WO2006056696A2 WO2006056696A2 (fr) 2006-06-01
WO2006056696A3 true WO2006056696A3 (fr) 2006-08-31

Family

ID=34951749

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002932 WO2006056696A2 (fr) 2004-11-29 2005-11-25 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation

Country Status (22)

Country Link
US (1) US7550453B2 (fr)
EP (1) EP1819679A2 (fr)
JP (1) JP2008521780A (fr)
KR (1) KR20070091120A (fr)
CN (1) CN101065362A (fr)
AR (1) AR052328A1 (fr)
AU (1) AU2005308710A1 (fr)
BR (1) BRPI0516666A (fr)
CA (1) CA2595305A1 (fr)
CR (1) CR9114A (fr)
EA (1) EA011392B1 (fr)
FR (1) FR2878528B1 (fr)
IL (1) IL183044A0 (fr)
MA (1) MA29030B1 (fr)
MX (1) MX2007006241A (fr)
NO (1) NO20073026L (fr)
PE (1) PE20061121A1 (fr)
TN (1) TNSN07137A1 (fr)
TW (1) TW200630343A (fr)
UY (1) UY29236A1 (fr)
WO (1) WO2006056696A2 (fr)
ZA (1) ZA200704342B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2878525B1 (fr) 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2901556A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation
FR2901554B1 (fr) 2006-05-24 2011-04-01 Sanofi Aventis 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation
FR2901555A1 (fr) * 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur preparation, compositions les contenant et utilisation
CN101092384A (zh) * 2006-06-22 2007-12-26 中国科学院上海药物研究所 一类α－氨基－N－取代酰胺化合物、其组合物及用途
CN101456824B (zh) * 2007-12-11 2013-04-17 中国科学院上海药物研究所 α-氨基-N-取代酰胺化合物、包含该化合物的药物组合物及其用途
WO2010072605A1 (fr) 2008-12-23 2010-07-01 F. Hoffmann-La Roche Ag Amides de dihydropyridone utiles comme modulateurs de p2x7
JP2012513435A (ja) 2008-12-23 2012-06-14 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ７調節薬としてのジヒドロピリドンアミド
CN102264723B (zh) 2008-12-23 2014-12-10 霍夫曼-拉罗奇有限公司 作为p2x7调节剂的二氢吡啶酮酰胺
US8153808B2 (en) 2008-12-23 2012-04-10 Roche Palo Alto Llc Dihydropyridone amides as P2X7 modulators
SG172385A1 (en) 2008-12-23 2011-08-29 Hoffmann La Roche Dihydropyridone amides as p2x7 modulators
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029382A1 (fr) * 1998-11-17 2000-05-25 Novartis Ag Caprolactames substitues, compositions pharmaceutiques contenant ces composes et leur utilisation dans le traitement des tumeurs
WO2001085697A1 (fr) * 2000-05-11 2001-11-15 Novartis Ag Carbonates et ethers de caprolactame substitues et utilisation de ceux-ci comme agents anti tumoraux
WO2002039990A2 (fr) * 2000-11-14 2002-05-23 Novartis Ag Methode de criblage de composes antiproliferatifs et methode permettant d'inhiber une croissance tumorale
WO2005014574A1 (fr) * 2003-07-25 2005-02-17 Novartis Ag Lactames substitues et utilisation de ceux-ci en tant qu'agents anti-cancereux

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692522A (en) 1985-04-01 1987-09-08 Merck & Co., Inc. Benzofused lactams useful as cholecystokinin antagonists
US4831135A (en) 1986-06-18 1989-05-16 The Regents Of The University Of California Bengamide anthelmintics
US5283241A (en) 1992-08-28 1994-02-01 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
GB9411841D0 (en) 1994-06-14 1994-08-03 Pharma Mar Sa New antitumoral compounds from jaspis sponge
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6239127B1 (en) 1999-11-17 2001-05-29 Novartis Ag Certain substituted caprolactams, pharmaceutical compositions containing them and a process for their preparation
US6545148B2 (en) 2001-03-12 2003-04-08 Novartis Ag Process for preparing certain substituted caprolactams
JP2004262793A (ja) 2003-02-28 2004-09-24 Noyaku Bio Technology Kaihatsu Gijutsu Kenkyu Kumiai 化合物ｎ−９０１１、その製造法及び用途
DE10349669B3 (de) 2003-10-24 2005-05-25 Aventis Pharma Deutschland Gmbh Bengamide-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US7153846B2 (en) 2003-10-24 2006-12-26 Sanofi-Aventis Deutschland Gmbh Bengamide derivatives, process for preparing them, and their use
FR2878525B1 (fr) * 2004-11-29 2007-02-23 Aventis Pharma Sa Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
FR2901555A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzothiazepine, leur preparation, compositions les contenant et utilisation
FR2901556A1 (fr) 2006-05-24 2007-11-30 Sanofi Aventis Sa Derives de 2-alcoxy-3,4,5-trihydroxy-alkylamide, leur preparation, compositions les contenant et utilisation
FR2901554B1 (fr) 2006-05-24 2011-04-01 Sanofi Aventis 2-alcoxy-3,4,5-trihydroxy-alkylamide-benzazepine, leur preparation, compositions les contenant et utilisation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029382A1 (fr) * 1998-11-17 2000-05-25 Novartis Ag Caprolactames substitues, compositions pharmaceutiques contenant ces composes et leur utilisation dans le traitement des tumeurs
WO2001085697A1 (fr) * 2000-05-11 2001-11-15 Novartis Ag Carbonates et ethers de caprolactame substitues et utilisation de ceux-ci comme agents anti tumoraux
WO2002039990A2 (fr) * 2000-11-14 2002-05-23 Novartis Ag Methode de criblage de composes antiproliferatifs et methode permettant d'inhiber une croissance tumorale
WO2005014574A1 (fr) * 2003-07-25 2005-02-17 Novartis Ag Lactames substitues et utilisation de ceux-ci en tant qu'agents anti-cancereux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GROWEISS A ET AL: "CYTOTOXIC METABOLITES FROM AN AUSTRALIAN COLLECTION OF THE SPONGE JASPIS SPECIES", JOURNAL OF NATURAL PRODUCTS, vol. 62, 1999, pages 1691 - 1693, XP002310389, ISSN: 0163-3864 *
KINDER F R ET AL: "SYNTHESIS AND ANTITUMOR ACTIVITY OF ESTER-MODIFIED ANALOGUES OF BENGAMIDE B", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 2001, pages 3692 - 3699, XP002310388, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
WO2006056696A2 (fr) 2006-06-01
TNSN07137A1 (en) 2008-11-21
PE20061121A1 (es) 2006-11-10
MX2007006241A (es) 2007-07-25
MA29030B1 (fr) 2007-11-01
CA2595305A1 (fr) 2006-06-01
AR052328A1 (es) 2007-03-14
BRPI0516666A (pt) 2008-09-16
NO20073026L (no) 2007-08-27
EA200701172A1 (ru) 2007-10-26
TW200630343A (en) 2006-09-01
US20070244087A1 (en) 2007-10-18
CN101065362A (zh) 2007-10-31
US7550453B2 (en) 2009-06-23
IL183044A0 (en) 2007-09-20
UY29236A1 (es) 2006-06-30
KR20070091120A (ko) 2007-09-07
FR2878528B1 (fr) 2008-05-16
ZA200704342B (en) 2008-07-30
EA011392B1 (ru) 2009-02-27
JP2008521780A (ja) 2008-06-26
FR2878528A1 (fr) 2006-06-02
CR9114A (es) 2008-01-21
EP1819679A2 (fr) 2007-08-22
AU2005308710A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
WO2007090393A3 (fr) Préparation pharmaceutique
WO2007019439A3 (fr) Compositions de copolymere sequence et utilisations de ces dernieres
PL375874A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
PL1792927T3 (pl) Nowy kopolimer blokowy, preparat micelarny i lek przeciwnowotworowy zawierający ten preparat micelarny jako składnik czynny
IL183044A0 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2004069152A3 (fr) ?4,5 glycuronidase et ses utilisations
EP1708719A4 (fr) Compositions pharmaceutiques aqueuses de 2,6-diisopropylphenol (propofol) et leurs utilisations
WO2007002823A3 (fr) Formulations d'oestrogenes conjugues et de bazedoxifene
WO2003000186A3 (fr) Nouvelles phenylamino-pyrimidines et leur utilisation
WO2007003264A3 (fr) Derives d'acide polyaspartique dans des produits de revetement contenant du polysiloxane
IL181216A0 (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
EP1828305A4 (fr) Preimpregne a faible perte, compositions utiles pour sa preparation et ses utilisations
WO2006056695A8 (fr) Bengamides possedant un cycle caprolactame substitue, procede de preparation, compositions les contenant et utilisation
WO2005097787A3 (fr) Derives de benzothiazoles capables de moduler l’activite des cdk et leur utilisation comme agents anticancereux
EP1797078A4 (fr) Derives de benzimidazole, compositions contenant ces derives, preparation et utilisations de ces derniers iii
AP2006003506A0 (en) Parasiticidal composition.
AU2003269871A1 (en) Radiosensitizer composition containing n-acetylphytosphingosine analogs and n,n-dimethyl-phytosphingosine analogs as the active ingredients
HU0304095D0 (en) Novel, effective pharmaceutical compositions
WO2006055663A3 (fr) Nouvelle utilisation
WO2004105780A3 (fr) Methodes et compositions contenant des composes de gastrine
IL195148A0 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzazepines, the preparation and use thereof and compositions containing the same
EP1578711A4 (fr) Composés diterpenoides, compositions les contenant et leur utilisation comme agents anticancereux ou antifongiques
IL191560A0 (en) 3,4-dihydrobenzoxazine derivatives and pharmaceutical compositions containing the same
EP1797074A4 (fr) Composes, compositions les contenant, leur preparation et leur utilisation
WO2006005017A3 (fr) Composition orale contenant un agent carbamoylant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2595305

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: DZP2007000249

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 183044

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12007500996

Country of ref document: PH

Ref document number: CR2007-009114

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2005822934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 555351

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/006241

Country of ref document: MX

Ref document number: 11753160

Country of ref document: US

Ref document number: 1867/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005308710

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007542046

Country of ref document: JP

Ref document number: 200580040746.4

Country of ref document: CN

Ref document number: 2007/04342

Country of ref document: ZA

Ref document number: 07053246

Country of ref document: CO

Ref document number: 1020077012024

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005308710

Country of ref document: AU

Date of ref document: 20051125

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005308710

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1200701307

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 200701172

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2005822934

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11753160

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0516666

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载